Due to the recent observation that MCTs may play a central part in tumor biology, and that MCT1 is considered as a potential target in cancer treatment, we aimed to explore the prognostic impact of MCT1–4 on disease specific survival (DSS) in both cancer and tumor stromal cells from NSCLC patients. Here, SLC16A1 is linked to neoplasm.